Skip to content

Study · Randomized controlled trial · n = 100 · 2021

5 results

Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.

Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J, Ma JY, Xu Y, Gao YN, Sun Y, Fan W, Liu W

The Journal of clinical endocrinology and metabolism1 Mar 2021Cited by 42 (Europe PMC)

PMID32995892 (opens in a new tab)PMCIDPMC8244122 (opens in a new tab)DOI10.1210/clinem/dgaa692 (opens in a new tab)PepBankPUB-32995892
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with PCOS and prediabetes, exenatide increased sustained remission versus metformin.

    In plain wordsExenatide increased sustained prediabetes remission compared with metformin in women with PCOS.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSustained prediabetes remission with exenatide
    Study

    n = 100

    Comparator
    Metformin
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10-20μg daily · 12 weeksAs given in this study (human).

    Measurements

    Sustained remission
    56%
    exenatide
    Sustained remission
    32%
    metformin

    Source sentences

    Summary
    Remission rate of COM group (64%, 32/50) or EX group (56%, 28/50) was significantly higher than that of the MET group (32%, 16/50) (P = .003 and .027, respectively).
    4 context sentences
    Summary · context
    Randomized, open-label, parallel-group controlled trial.
    Summary · context
    PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol/L and/or 2 hour post glucose 7.8-11.0 mmol/L on oral glucose tolerance test [OGTT]).
    Summary · context
    EX (10-20μg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12 weeks.
    Summary · context
    Sustained remission rate of prediabetes (primary endpoint, a normal OGTT after 12 weeks of treatment followed by 12 weeks of washout on no drug treatment) along with anthropometric, hormonal, metabolic, and pancreatic β-cell function parameters (secondary endpoints) and potential mechanisms were assessed.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with PCOS and prediabetes, adding exenatide to metformin increased sustained remission versus metformin alone.

    In plain wordsExenatide plus metformin increased sustained prediabetes remission compared with metformin alone in women with PCOS.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSustained prediabetes remission with combination
    Study

    n = 100

    Comparator
    Metformin
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10-20μg daily · 12 weeksAs given in this study (human).

    Measurements

    Sustained remission
    64%
    exenatide plus metformin
    Sustained remission
    32%
    metformin

    Source sentences

    Summary
    Remission rate of COM group (64%, 32/50) or EX group (56%, 28/50) was significantly higher than that of the MET group (32%, 16/50) (P = .003 and .027, respectively).
    4 context sentences
    Summary · context
    Randomized, open-label, parallel-group controlled trial.
    Summary · context
    PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol/L and/or 2 hour post glucose 7.8-11.0 mmol/L on oral glucose tolerance test [OGTT]).
    Summary · context
    EX (10-20μg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12 weeks.
    Summary · context
    Sustained remission rate of prediabetes (primary endpoint, a normal OGTT after 12 weeks of treatment followed by 12 weeks of washout on no drug treatment) along with anthropometric, hormonal, metabolic, and pancreatic β-cell function parameters (secondary endpoints) and potential mechanisms were assessed.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with PCOS and prediabetes, exenatide was associated with superior suppression of the 2-hour OGTT glucose increment.

    In plain wordsIn women with PCOS and prediabetes, exenatide was linked to stronger suppression of the blood sugar rise after a glucose test.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Decrease2-hour OGTT glucose increment
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10-20μg daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    EX was associated with superior suppression of 2-hour glucose increment in OGTT.
    4 context sentences
    Summary · context
    Randomized, open-label, parallel-group controlled trial.
    Summary · context
    PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol/L and/or 2 hour post glucose 7.8-11.0 mmol/L on oral glucose tolerance test [OGTT]).
    Summary · context
    EX (10-20μg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12 weeks.
    Summary · context
    Sustained remission rate of prediabetes (primary endpoint, a normal OGTT after 12 weeks of treatment followed by 12 weeks of washout on no drug treatment) along with anthropometric, hormonal, metabolic, and pancreatic β-cell function parameters (secondary endpoints) and potential mechanisms were assessed.
  4. 04HumanRandomized controlled trialMechanism

    In women with PCOS and prediabetes, exenatide produced higher postprandial insulin secretion than metformin in clamp testing.

    In plain wordsExenatide increased insulin release after meals more than metformin in women with PCOS and prediabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePostprandial insulin secretion
    Study

    n: not reported in source

    Comparator
    Metformin
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10-20μg daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    A 2-step hyperglycemic clamp study revealed that EX had led to higher postprandial insulin secretion than MET, potentially explaining the higher remission rate.
    4 context sentences
    Summary · context
    Randomized, open-label, parallel-group controlled trial.
    Summary · context
    PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol/L and/or 2 hour post glucose 7.8-11.0 mmol/L on oral glucose tolerance test [OGTT]).
    Summary · context
    EX (10-20μg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12 weeks.
    Summary · context
    Sustained remission rate of prediabetes (primary endpoint, a normal OGTT after 12 weeks of treatment followed by 12 weeks of washout on no drug treatment) along with anthropometric, hormonal, metabolic, and pancreatic β-cell function parameters (secondary endpoints) and potential mechanisms were assessed.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In women with PCOS and prediabetes, overall sustained remission across exenatide, metformin and combination arms was 50.7%.

    In plain wordsAcross all treatment groups, about half of the women with PCOS and prediabetes achieved sustained remission.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableOverall sustained prediabetes remission
    Study

    n = 150

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Overall sustained remission
    50.7%
    all treatment arms

    Source sentences

    Summary
    Overall sustained prediabetes remission rate was 50.7%.
    4 context sentences
    Summary · context
    Randomized, open-label, parallel-group controlled trial.
    Summary · context
    PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol/L and/or 2 hour post glucose 7.8-11.0 mmol/L on oral glucose tolerance test [OGTT]).
    Summary · context
    EX (10-20μg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12 weeks.
    Summary · context
    Sustained remission rate of prediabetes (primary endpoint, a normal OGTT after 12 weeks of treatment followed by 12 weeks of washout on no drug treatment) along with anthropometric, hormonal, metabolic, and pancreatic β-cell function parameters (secondary endpoints) and potential mechanisms were assessed.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03352869

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

RenJi Hospitaln = 18328 Nov 2017 to 31 Jul 2018

Polycystic Ovary Syndrome · Overweight and Obesity · Disorder of Glucose Regulation

Trial pageClinicalTrials.govUpdated 11 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.